KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Asset Writedowns and Impairment (2022 - 2025)

Pacific Biosciences Of California (PACB) has 4 years of Asset Writedowns and Impairment data on record, last reported at $6.5 million in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 107.29% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $15.0 million, down 84.02%, while the annual FY2025 figure was $15.0 million, 224.82% up from the prior year.
  • Asset Writedowns and Impairment reached $6.5 million in Q4 2025 per PACB's latest filing, up from $883000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $93.2 million in Q2 2024 and bottomed at -$88.6 million in Q4 2024.
  • Average Asset Writedowns and Impairment over 4 years is $7.8 million, with a median of $880500.0 recorded in 2022.
  • The widest YoY moves for Asset Writedowns and Impairment: up 22444.95% in 2024, down 1788.34% in 2024.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at -$2.7 million in 2022, then plummeted by 75.89% to -$4.7 million in 2023, then plummeted by 1788.34% to -$88.6 million in 2024, then skyrocketed by 107.29% to $6.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $6.5 million in Q4 2025, $883000.0 in Q2 2025, and $7.7 million in Q1 2025.